Mow Jonathan P
Insider CIK 1313942 · PHAS Chief Executive Officer, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| PHAS PhaseBio Pharmaceuticals I | A Award | 2022-05-20 | 2022-05-24 | 10,918 | $0.68 | $7.4K | 132,502 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | A Award deriv | 2022-02-24 | 2022-02-28 | 385,000 | — | $0 | 385,000 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | A Award deriv | 2022-02-24 | 2022-02-28 | 82,500 | — | $0 | 82,500 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | A Award | 2021-11-19 | 2021-11-23 | 5,623 | $2.01 | $11.3K | 172,473 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise deriv | 2021-11-03 | 2021-11-03 | 20,000 | $1.24 | $24.8K | 108,767 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise | 2021-11-03 | 2021-11-03 | 20,000 | $1.24 | $24.8K | 166,850 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise deriv | 2021-08-27 | 2021-08-30 | 20,000 | — | $0 | 128,767 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise | 2021-08-27 | 2021-08-30 | 20,000 | $1.24 | $24.8K | 146,850 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | A Award | 2021-05-20 | 2021-05-24 | 3,964 | $2.80 | $11.1K | 126,850 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | A Award deriv | 2021-02-05 | 2021-02-09 | 234,000 | — | $0 | 234,000 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | A Award | 2020-11-20 | 2020-11-23 | 3,643 | $3.00 | $10.9K | 122,886 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise deriv | 2020-08-21 | 2020-08-24 | 10,000 | — | $0 | 148,767 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise | 2020-08-21 | 2020-08-24 | 10,000 | $1.24 | $12.4K | 119,243 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | A Award deriv | 2020-02-12 | 2020-02-14 | 290,000 | — | $0 | 290,000 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise deriv | 2019-09-06 | 2019-09-10 | 19,000 | — | $0 | 158,767 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise | 2019-09-06 | 2019-09-10 | 19,000 | $1.24 | $23.6K | 109,243 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise deriv | 2019-05-20 | 2019-05-21 | 19,131 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise | 2019-05-20 | 2019-05-21 | 19,131 | $1.24 | $23.7K | 90,243 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise deriv | 2019-05-17 | 2019-05-21 | 19,913 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise | 2019-05-17 | 2019-05-21 | 19,913 | $2.27 | $45.2K | 71,112 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | A Award deriv | 2019-02-27 | 2019-03-01 | 263,000 | — | $0 | 263,000 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | P Buy | 2018-12-13 | 2018-12-17 | 1,000 | $3.69 | $3.7K | 51,199 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | P Buy | 2018-12-10 | 2018-12-11 | 800 | $3.85 | $3.1K | 51,699 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | P Buy | 2018-12-10 | 2018-12-13 | 800 | $3.85 | $3.1K | 50,199 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | P Buy | 2018-12-07 | 2018-12-11 | 2,200 | $3.88 | $8.5K | 50,899 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | P Buy | 2018-12-07 | 2018-12-13 | 700 | $3.89 | $2.7K | 49,399 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 3,505 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise deriv | 2018-10-22 | 2018-10-24 | 310 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | M Exercise deriv | 2018-10-22 | 2018-10-24 | 310 | $0.12 | $37 | 310 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 310 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion | 2018-10-22 | 2018-10-24 | 3,505 | — | $0 | 48,699 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion | 2018-10-22 | 2018-10-24 | 310 | — | $0 | 310 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | A Award deriv | 2018-10-17 | 2018-10-17 | 220,000 | — | $0 | 220,000 | SEC↗ |